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Purpose. We hypothesized that sustained delivery of vascular endothelial growth factor (VEGF) using a
polymer [85:15 poly(lactide-co-glycolide) (PLG)] would enhance angiogenesis and improve perfusion of
ischemic tissue.
Methods. C57BL/6J mice (n = 20/group) underwent unilateral hind limb ischemia surgery and were
randomized to groups of no scaffold implantation (;-Implant), unloaded scaffold implantation (Empty-
PLG), or implantation of scaffolds incorporating 3 mg of VEGF165 (PLG-VEGF). Endpoints included
laser Doppler perfusion imaging (LDPI, ischemic/nonischemic limb, %), local vessel counts, im-
munohistochemistry for CD31, and a-smooth muscle actin. In vitro release kinetics of VEGF from PLG
was also measured.
Results. PLG-VEGF resulted in improved lower extremity perfusion vs. controls as measured by
LDPI% at 7, 14, 21, and 28 days (p < 0.05). PLG-VEGF was associated with significantly greater
percentage of vessels staining for CD31 and a-smooth muscle actin compared to the Empty-PLG or
;-Implant ( p < 0.05 for both).
Conclusions. The PLG-VEGF scaffolds resulted in sustained VEGF delivery, improved tissue perfusion,
greater capillary density, and more mature vasculature compared to the controls. The sustained-release
PLG polymer vehicle is a promising delivery system for therapeutic neovascularization applications.
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INTRODUCTION
There exists a critical need for new therapies to treat
ischemic peripheral arterial disease (PAD). Strategies de-
signed to enhance lower extremity blood flow via therapeutic
angiogenesis/arteriogenesis are attractive modalities because
they address the fundamental issue of limited blood flow in
PAD (1). Preclinical and clinical efforts to accomplish the
latter goal have focused on systemic delivery of proangio-
genic growth factors or regional delivery approaches using
gene transfer at the site of ischemia (2). Whereas several
growth factors, including vascular endothelial growth factor
(VEGF), initiate new blood vessel growth, protracted
expression of VEGF may be required for activation of
endothelial and hematopoietic progenitor cells (3) and for
maintenance of stable neovessels (4). Current gene transfer
approaches with viral or plasmid vectors have limitations
related to their duration of expressionVoften less than 3
weeks (5). This may represent one reason underlying the
failure of human clinical trials with gene transfer approaches
for patients with PAD (6) and has led to an interest in
techniques designed to increase the local concentration, time
of growth factor exposure, or both. A polymer-based drug
delivery vehicle has several potential advantages including
protracted and localized drug delivery (7Y9). One promising
drug delivery system utilizes a biodegradable polymer of
lactide and glycolide [poly(lactide-co-glycolide), PLG]
(10Y12). This polymer was developed as a biodegradable
suture (13) and has a long history of use in humans. The
many advantageous features of PLG (e.g., controlled degra-
dation, well-established tissue interaction, etc.) make it an
attractive vehicle for drug delivery. The rationale underlying
this approach is that the bioactive molecule, e.g., VEGF, is
incorporated into the polymer and then implanted at the site
of desired administration. The bioactive factor is slowly and
controllably released from the polymer (e.g., via polymer
degradation), with the dose and rate of delivery dependent
on the amount of drug loaded, the process used for drug
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ABBREVIATIONS: Empty-PLG, PLG polymer not loaded with
growth factor; ;-Implant, hind limb surgery performed with no PLG
polymer implanted; PAD, peripheral arterial disease; PLG,
poly(lactide-co-glycolide); PLG-VEGF, PLG polymer loaded with
3 mg of VEGF165; SMA, smooth muscle actin; VEGF, vascular
endothelial growth factor.
incorporation, and the polymer used to fabricate the vehicle
(14). VEGF delivery with various PLG vehicles has been
previously reported to enhance local neovascularization
(7,12,15,16), but the functional impact of this vascularization
on tissue perfusion has not been reported.
In this study, we hypothesized that sustained delivery of
VEGF using a degradable polymer scaffold (85:15 PLG)
incorporating human VEGF165 would result in development
of mature vasculature and improvements in perfusion in a
murine model of hind limb ischemia. A mouse hind limb
ischemia model was used in this study. Endpoints included
tissue perfusion with laser Doppler, immunohistochemical
indicators for neovascularization that included the endothe-
lial cell marker CD31 (17) and a-smooth muscle actin (a-
SMA) (18), which is expressed in both pericytes and smooth
muscle cells and is associated with mature blood vessels.
MATERIALS AND METHODS
Animals and Surgical Procedures
Sixty male C57BL/6J mice (Jackson Laboratories, Bar
Harbor, ME, USA) aged 6 weeks were used in these studies.
Animals were handled according to a protocol approved by
the University of Michigan Committee on Use and Care of
Animals. Mice were cared for according to standards in the
Guide for the Care and Use of Laboratory Animals. Before
the surgical procedures, the mice were anesthetized with an
intraperitoneal injection of a mixture of ketamine 80 mg/kg
and xylazine 5 mg/kg. Severe unilateral hind limb ischemia
was surgically created via ligation and division of the left
superficial femoral artery and vein, left external iliac artery
and vein, and left deep femoral and circumflex arteries and
veins. The consistency of limb ischemia and the prognosis
associated with this model was previously confirmed in our
laboratory (data not shown). At the time of surgery, mice
were randomized to one of three groups (n = 20 per group):
immediate implantation of PLG scaffold containing VEGF
(PLG-VEGF), PLG scaffold containing no growth factor
(Empty-PLG), or no PLG scaffold (;-Implant). The scaffolds
were implanted in the thigh region adjacent to the ligated
vessels.
Scaffold Fabrication and Analysis of Release Kinetics
in Vitro
Porous polymer scaffolds capable of VEGF release in a
sustained pattern were fabricated from PLG using a variation
of a high-pressure carbon dioxide fabrication process as
previously described (15). Briefly, all scaffolds were formed
by an identical process of mixing PLG in the form of mi-
crospheres (particle size 5Y50 mm in diameter), T 4 mg of
human VEGF165 lyophilized with alginate and sodium chlo-
ride particles. The inclusion of alginate has been previously
demonstrated to increase the efficiency of protein incorpo-
ration into the PLG vehicle (7). The VEGF incorporation
efficiency has been previously measured for this system
(7,15), and the amount of VEGF used to form scaffolds re-
sults in 3 mg of VEGF in each scaffold at the end of the
fabrication process. The PLG, VEGF165, and sodium chloride
were mixed, compressed, and equilibrated with high-pres-
sure carbon dioxide. When the pressure was released, the
PLG particles expanded into the spaces between the salt
particles and fused, entrapping VEGF and the salt. Subse-
quently, the salt particles were removed by leaching with
water to yield porous scaffolds (14,15,19). Scaffolds for in
vitro release kinetics studies were fabricated with 3 mg of 125I-
VEGF tracer using an identical process, and the in vitro
release studies were performed as previously described (15).
In the release studies, the amount of VEGF incorporated
into each scaffold is measured before starting the study (using
the known specific activity of the iodinated VEGF), and
release is normalized to the total VEGF incorporated into
each scaffold. All scaffolds were 4.2 mm in diameter by
2.3 mm thick.
Fig. 1. In vitro cumulative release kinetics of VEGF from
scaffolds fabricated from PLG (85:15, lactide/glycolide), mea-
sured using 125I-labeled tracers. Data represent the mean (n = 5),
and error bars represent standard deviation.
Fig. 2. Computer-assisted quantitative analyses of LDPI indices of
hind limb blood flow in C57BL/6J mice. Blood flow was expressed as
ischemic limb/untreated limb perfusion in mice implanted with PLG-
VEGF scaffolds compared with mice implanted with blank scaffolds
or mice with sham surgery (no scaffold implantation). *, p < 0.05,
PLG-VEGF vs. Empty-PLG or ;-Implant scaffold, n = 3Y5 at each
time point and each group.
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Laser Doppler Perfusion Imaging
Hind limb blood flow was measured using a laser
Doppler perfusion imaging (LDPI) system (Lisca Inc., Link-
öping, Sweden). Consecutive perfusion measurements were
obtained by scanning the region of interest (hind leg and
foot) of anesthetized animals. To account for variables that
may affect blood flow temporally, the results at any given
time were expressed against simultaneously obtained perfu-
sion measurements as a ratio, i.e., left (ischemic)/right
(normal) limb perfusion (20).
Histological and Immunohistochemical Analysis
Mice from each group were sacrificed at postsurgical
days 7, 14, 21, and 28, and muscle and residual scaffolds were
retrieved from the ischemic hind limb of each animal. The
samples were fixed in 10% zinc formalin overnight, paraffin
embedded, and sectioned into 5-mm-thick sections that were
then stained with hematoxylin and eosin for histological
analysis. Positive CD31 staining was visualized using a rat
monoclonal antimouse plateletYendothelial cell adhesion
molecule (PECAM)-1 antibody (CD31, 1:250, Pharmingen,
San Diego, CA. USA), a biotinylated rabbit antirat IgG
secondary antibody (1:200, Vector Laboratories, Burlingame,
CA, USA), and NEN TSA Biotin System (NEL 700. Perkin
Elmer Life Sciences, Boston, MA, USA) was used to visu-
alize the bound antibodies. Omission of the primary antibody
and replacement of the primary antibody by nonimmune IgG
were used as a negative control for immunohistochemistry.
The a-SMA staining was performed using the Mouse on
Mouse (MOM) Peroxidase Immunodetection kit (Vector
Laboratories), primary antibody of mouse antihuman (1:50,
Dako Cytomation, Carpinteria, CA, USA) and MOM sec-
ondary antibody.
Vessel densities calculated from slides stained for CD31
were expressed as capillaries per millimeter squared. To
obtain the average vessel number per cross-sectional area, a
Fig. 3. Representative images of CD31 expression from thigh muscle of C57BL/6J
mice treated by Empty-PLG (A-2), PLG-VEGF (A-3), or hind limb ischemia surgery
with no PLG scaffold implanted (;-Implant) (A-1); and from retrieved scaffolds from
Empty-PLG (B-1) and PLG-VEGF scaffold (B-2) at day 28. There are more dark-
staining CD31 positive capillary vessels (arrows) in the PLG-VEGF group than in the
Empty-PLG scaffold or ;-Implant groups. Magnification for all photomicrographs was
200.
1112 Sun et al.
minimum of ten individual fields per slide were sampled, and
Image Pro-plus 4.0 (Media Cybernetics, Silver Spring, MD,
USA) was used to measure the counted field area. The
number of CD31 positively stained blood vessels was counted
manually. Only those CD31 positive vessels with a morpho-
logical circumference of one or greater endothelial cells were
tallied as capillary vessels. CD31 staining consisting of a
single cell was not counted as a capillary. The number of
vessels associated with a-SMA positively stained cells was
also quantified in a similar fashion.
Materials and Chemicals
PLG (85:15, intrinsic viscosity = 1.5 dL/g) was purchased
from Alkermes (Cambridge, MA, USA). High molecular
weight alginate (MVM) was obtained from ProNova (Oslo,
Norway). VEGF165 was purchased from Intergen (Purchase,
NY, USA). Radiolabeled 125I-VEGF was purchased from
Perkin Elmer Life Sciences (Boston, MA, USA).
Statistical Analysis
All values were expressed as mean T SD, and were
analyzed by two-way ANOVA with post hoc Friedman test
using GraphPad Prism software (version 3.00, GraphPad
Software, Inc., San Diego, CA, USA). A p value <0.05 was
considered significant.
RESULTS
In Vitro Kinetics of VEGF Release
Figure 1 demonstrates the in vitro kinetics of VEGF
release in the scaffolds as assessed using 125I-VEGF.
Approximately 50% of the VEGF was released from the
PLG scaffold within 3 days. Subsequently, over the next
30 days, the VEGF release rate was approximately 1Y3%
per day.
Lower Extremity Perfusion with VEGF Delivery via
Biodegradable Scaffolds
Figure 2 illustrates the LDPI index data in the three
groups. In all groups, LDPI indices decreased immediately
after surgery. In the ;-Implant and Empty-PLG groups, the
LDPI index remained <20% for 10 days and then gradually
increased to 42 T 6 and 54 T 4%, respectively by day 28 (p =
ns). In contrast, the LDPI index in the PLG-VEGF group
increased over time, was significantly greater than the other
groups by day 7, and was persistently greater than the other
groups throughout the remainder of the study (p < 0.05 for
PLG-VEGF vs. other groups on days 7, 14, 21, and 28).
Indices of Angiogenesis in Response to VEGF Scaffold
Implantation
Blood vessels were quantified in both the ischemic
muscle tissue and within the space defined by the PLG
delivery vehicles. The latter measurement reflects only the
angiogenic response, as any vessels within the PLG must be
newly formed. In contrast, both angiogenesis and arterio-
genesis may be occurring in the muscle tissue. Muscle tissue
capillary vessel density was significantly greater in the PLG-
VEGF group compared to the Empty-PLG or ;-Implant
group on days 14, 21, and 28 (p < 0.05 for PLG-VEGF vs.
other groups) (Figs. 3 and 4A). In addition, there were sig-
nificantly more capillary vessels in the retrieved scaffolds on
days 21 and 28 (p < 0.05 for PLG-VEGF vs. other groups)
(Figs. 3 and 4B). PLG-VEGF scaffold implantation was also
associated with increased a-SMA staining in the thigh muscle
tissue compared to Empty-PLG and ;-Implant (p < 0.05 for
PLG-VEGF vs. other groups) (Figs. 5 and 6). Similarly,
vessels in the PLG-VEGF retrieved scaffolds had signifi-
cantly more a-SMA staining compared to the Empty-PLG
scaffold group (Figs. 5 and 6).
DISCUSSION
The main findings of this study are the following. (1)
Sustained growth factor presentation is feasible in the lower
extremity using a biodegradable platform. (2) Protracted
local presentation of VEGF is paralleled by improved lower
extremity perfusion, greater capillary density, and more
mature vasculature formation compared to the controls.
These data support the concept of using polymer drug
Fig. 4. Capillary densities after CD31 stain in thigh muscle (A) or
retrieved scaffolds (B) of mice. There was significantly greater cap-
illary density per square millimeter of ischemic tissue observed in
mice treated by PLG-VEGF implantation vs. Empty-PLG or ;-
Implant implantation at postoperative days 14, 21, and 28. Similarly,
there were significantly more capillary vessels in the retrieved scaf-
folds from the PLG-VEGF group compared to the retrieved Empty-
PLG scaffolds at days 21 and 28. Mean TSD (*p < 0.05).
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delivery to allow controlled sustained release of a bioactive
factor (or factors). This study confirms and extends previous
observations regarding VEGF delivery that have demon-
strated improved indices of perfusion in the lower extremity
with bolus delivery (21Y24). However, this new delivery
platform affords the opportunity to evaluate the effect of
more protracted release of VEGF. This is especially impor-
tant in light of observations that seem to suggest that the
duration of exposure to VEGF may be a critical determinant
of formation of stable neovasculature (25,26).
The PLG vehicle used in this study has several potential
advantages for delivery of therapeutic angiogenesis agents.
The PLG polymer is biocompatible, degradable (27), and
has been widely used in tissue engineering applications
(7,12,14,28Y33). Because the growth factor release rate and
tissue dose can be altered by adjusting polymer vehicle
formulation (19,27), the ability to influence local pharmaco-
kinetics of the growth factor is substantial, and desired
neovascular effects are achievable. The in vitro kinetics of
VEGF release from the PLG system was similar to those
previously reported with this approach to protein incorpora-
tion (12,14,15), but the different scaffold sizes, compositions,
and physical forms of PLG used to fabricate the scaffolds
(microparticles vs. preformed microspheres) in the various
studies all can influence the release kinetics achievable with
this system. Although not evaluated in this study, it has
previously been demonstrated that VEGF incorporated and
released over a 1-month period using this delivery system
maintains a high level of bioactivity (15).
For this proof of concept investigation, VEGF was
chosen because it has been demonstrated to promote neo-
vascularization in preclinical studies (6,34,35). VEGF is a
multifunctional cytokine with potent vascular permeabilizing
properties that stimulates endothelial cell migration, surviv-
al, and growth, and its effects on angiogenesis may be via
direct action on endothelial cells and less direct effects
involving other cells types in addition (36). In this study,
PLG-VEGF-treated mice had increased hind limb blood
flow, increased capillary density, and a sustained local tissue
concentration of VEGF detectable for 14 to 28 days (data
not shown). Previous studies with a PLG-VEGF scaffold
manufactured with the technique identical to that used in
Fig. 5. Representative images of a-SMA staining of ischemic limb thigh muscle tissue
of mice subjected to hind limb ischemia surgery without scaffold implantation (;-
Implant) (A-1), Empty-PLG (A-2), PLG-VEGF (A-3) and from retrieved scaffolds
from Empty-PLG (B-1) and PLG-VEGF (B-2) at day 28. There are more a-SMA
positive-staining vessels (arrows) in the PLG-VEGF group than in Empty-PLG or ;-
Implant group. Magnification for all photomicrographs was 200.
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this study have confirmed that protein activity is maintained
during scaffold fabrication and over a 1-month release
period (15). The previous study also demonstrated that
bolus delivery of an amount of VEGF equal to that incor-
porated into the PLG delivery vehicle led to no significant
increase in capillary density, likely due to the extremely
short half-life of this molecule when introduced unprotected
into the body (15).
The PLG-VEGF group was associated with more
mature blood vessels as determined by a-SMA staining. This
effect was seen in the muscle tissue, where this effect could
be related to angiogenesis or arteriogenic alterations of
preexisting vessels. However, the same effect was also noted
within the space defined by the scaffold, in which all blood
vessels must result from angiogenesis, indicating that the
angiogenic process is being regulated by sustained VEGF
delivery with this system. Interestingly, the relative diameter
of vessels staining positive for a-SMA was not significantly
different among groups after 4 weeks (data not shown). This
suggests that VEGF alone may be insufficient to induce
vessel enlargement under the conditions of this study, and the
action of additional factors such as platelet-derived growth
factor may be required (15). Whether longer-term exposure
to VEGF or combinations with other cytokine(s) would
result in larger, more arteriolar appearing vasculature in
ischemic tissue is under investigation.
CONCLUSION
Sustained VEGF delivery using the PLG polymer
system results in improved tissue perfusion, greater capillary
density, and more mature-appearing vasculature compared to
the controls. These data extend previous in vitro and in vivo
studies and suggest that this polymer system is a promising
delivery approach for therapeutic angiogenesis and arterio-
genesis.
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